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Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) 
are now included in most guidelines for treatment of type 
2 diabetes, most recently in the Consensus Report by the 
European Society for the Study of Diabetes (EASD) and 
the American Diabetes Association (ADA) (1). However, 
it is still just a few percent of the diabetes patients that 
actually receive GLP-1 RA therapy. This is an interesting 
paradox which needs serious contemplation. It may of 
course be related to trivial matters such as pricing and the 
need for injections, but perhaps also bad reputation due to 
the side effects (nausea etc.) and the previous accusations of 
associations with cancers and pancreatitis, concerns that no 
longer receive much attention. In view of the documented 
beneficial effects of these drugs, this is something the health 
care providers should consider more carefully.
GLP-1 RAs are available in several forms with 
remarkably different characteristics. The short-acting 
agonists comprise exenatide and lixisenatide with a 
duration of action of only few hours after subcutaneous 
(s.c.) injections. Long acting agonists include liraglutide 
(once daily), and exenatide once weekly (ow), albiglutide, 
dulaglutide and semaglutide which, except for liraglutide, 
are intended for weekly s.c. administration. The long acting 
agonists are all capable of maintaining a relevant agonist 
level in plasma throughout the 24 hours of the day, although 
the actual profiles may show some variation (perhaps most 
with liraglutide and least with semaglutide). Today, there 
is little doubt that the long acting GLP-1 RAs have better 
overall effects than the short acting RAs. 
The GLP-1 RAs all build on the actions of the intestinal 
hormone, GLP-1, as mediated by its interaction with the 
G-protein coupled GLP-1 receptor. GLP-1 was isolated as 
an insulin-stimulating hormone (2), and the beta cells also 
show a particularly dense expression of the GLP-1 receptor. 
The receptor couples to the Gs protein (3) which activates 
adenylate cyclase and via cAMP formation activates 
protein kinase A. Many of the subsequent actions can be 
ascribed to the protein kinase A activation, but activation of 
guanine nucleotide exchange factor II (epac 2) also plays an 
important role. Growth effects on beta cells are probably 
mediated via the PI-3 kinase pathway (4). In terms of insulin 
secretion, the effect of the GLP-1 RAs is usually described 
as a potentiation of glucose-induced insulin secretion. More 
precisely, the GLP-1 RAs improve the sensitivity of the beta 
cell to glucose. This parameter may in humans be estimated 
from the slope of insulin secretory rates (as determined 
from C-peptide pharmacokinetics and deconvolution) 
versus a range of plasma glucose concentrations obtained by 
glucose infusions at increasing rates; it has the dimension: 
nmoles of insulin secreted per min, per kg, per increase 
in glucose concentration (mM) (5). This slope is severely 
reduced in type 2 diabetes mellitus (T2DM), but may be 
virtually normalized by the normal therapeutic doses of 
GLP-1 (5). This explains that insulin concentrations usually 
are not changed during chronic therapy with a GLP-1 
RA (6). What is observed is a maintained insulin secretion 
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occurring in spite of lower glucose levels. In other words, 
the beta cells have been sensitized to glucose, enabling them 
to produce the same amount of insulin in spite of lower 
glucose levels. 
However, GLP-1 and the GLP-1 RAs have numerous 
other actions that are extremely important for their clinical 
actions. A list of these actions is provided as Table 1. 
Numerous GLP-1 actions are mentioned in various 
reviews and publications, but common to most of the 
alleged actions, they have not been rigorously confirmed 
and/or their human relevance has not been ascertained. 
Point no. (I) on the list deals with the glucose sensitivity 
of the beta cells as already discussed, but also the alpha cells 
are affected. It is usually described that GLP-1 inhibits 
alpha cell secretion, and this is easily observed also in 
patients with T2DM upon GLP-1 infusion (2). In one 
study, glucagon secretion was studied in T2DM during a 
glucose clamp, and whereas glucagon secretion was rapidly 
and profoundly suppressed in glucose tolerant matched 
control subjects, the patients showed a delayed and reduced 
suppression (7). A superimposed GLP-1 infusion, however, 
completely restored the glucose-induced suppression, 
suggesting that also the alpha cell sensitivity to glucose 
may be restored by GLP-1. It has been demonstrated that 
the inhibition of glucagon secretion may be responsible 
for at least 50% of the glucose lowering effects of GLP-1 
in T2DM patients (8). Given that the effects of GLP-1 on 
alpha cell secretion mainly consist of facilitating suppression 
by glucose, then this may also explain that GLP-1 and the 
GLP-1RAs do not at all suppress glucagon responses to 
hypoglycemia (i.e., no glucose) (6).
Bullet (II), beta cell protection is clearly observed in 
numerous animal experiments, but human beta cells do 
not seem to respond to GLP-1 with proliferation, perhaps 
because this effect may only be observed in very young beta 
cells. Inhibition of apoptosis might also lead to beta cell 
protection but is it observed in humans? Two clinical studies 
suggest that there may be a protective effect: one is the 3 
years study where intensive therapies with either exendin 4 
or insulin were compared. In both groups beta cell function 
was preserved over a period of 3 years (9). In the course of 
3 years, one would have expected some impairment of beta 
cell function to occur in patients with T2DM, so it may 
be concluded that GLP-1 therapy was indeed protective, 
but that intensive insulin therapy was similarly protective 
(which may be true). In the LEADER cardiovascular 
outcome trial of liraglutide (10), therapy was continued for 
up to 5 years in >9,000 T2DM patients, and it turned out 
that HbA1c levels were fairly well maintained throughout 
this period. Again, a deterioration of beta cell function 
would have been expected in this large group of patients 
with longstanding diabetes, so perhaps there is some beta 
cell protection after all. 
Bullet (III), inhibition of gastric emptying is one of the 
most conspicuous actions of native GLP-1, and also the 
long acting GLP-1 RAs inhibit gastric emptying to some 
extent (11), in spite of the pronounced tachyphylaxis elicited 
during chronic therapy. This mechanism, therefore, does to 
some extent contribute to the effects of chronic GLP-1 RA 
treatment. 
(IV) The weight loss effects of the GLP-1 RAs are of 
paramount importance, but here we find some important 
differences between the GLP-1RAs, with very weak effects 
exerted by albiglutide (12) and very strong effects exerted 
by semaglutide (13) although they have not yet all been 
compared in head-to-head studies (which are indispensable 
for such comparisons). The mechanism of action is still 
somewhat unclear—there is no increase in energy expenditure 
to explain weight loss, but the evidence points to inhibition 
of appetite as the driver of the decrease in food intake. There 
is evidence that the inhibition of appetite is exerted via 
centers in the brain, including hypothalamic centers as well as 
centers related to the reward system. Regulation of both the 
AGRP/NPY neurons and the POMC/CART neurons in the 
arcuate nucleus may play an important role (14). Endogenous 
GLP-1 is thought to signal to the brain via sensory afferents 
of the vagus nerve (15), terminating in the nucleus of 
the solitary tract in the brain stem, whereas exogenous 
GLP-1 and the GLP-1RAs probably mainly reach the 
Table 1 Possible actions of GLP-1 and the GLP-1 RAs
(I) Reset alpha and beta cell sensitivity to glucose
(II) Beta cell protection
(III) Inhibition of gastric emptying, gastrointestinal motility and 
gastrointestinal secretions 
(IV) Inhibition of appetite and food intake
(V) No direct effect on liver, adipose tissue, skeletal muscle
(VI) Kidneys: increased sodium excretion—effects on afferent  
arterioles
(VII) Immune system: intestinal intraepithelial lymphocytes
(VIII) Interaction with enteric nervous system
(IX) Receptors in the heart—increased heart rate; other?
GLP-1, glucagon-like peptide-1; RAs, receptor agonists.
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brain via the leaks of the blood brain barrier in the 
circumventricular organs, notably the area postrema, the 
median eminence and the subfornical organ (14). This may 
also explain some of the differences between the GLP-
1 RAs regarding inhibition of food intake. Liraglutide 
and semaglutide are noncovalently bound to albumin and 
therefore act as protein-bound hormones, where the free 
fraction is responsible for the biological activity. Free sema- 
or lira-glutide may reach regions in the brain that the 
macro-molecules, dulaglutide and albiglutide (in which the 
GLP-1 moiety is covalently bound to a large molecule), can 
access only with difficulty. For exenatide ow, the two mg 
dose developed may simply be too low to compete with the 
relatively higher doses of lira and sema-glutide.
The effects on lipid metabolism of the GLP-1 RAs are 
unclear; lowering of postprandial triglyceride levels has been 
reported (11), but is difficult to separate from the effects on 
gastric emptying. Long term studies with lira- and sema-
glutide [LEADER and SUSTAIN 6 (10,16)] did not reveal 
major changes in plasma lipid concentrations, and the small 
changes actually observed could also be associated with the 
weight loss in these studies. 
(V) Importantly, there are no convincing studies to 
suggest that there are direct actions of the GLP-1 RAs on 
the liver (hepatocytes), the adipose tissue (white adipocytes) 
or the skeletal muscles (myocytes). However, this does not 
exclude possible actions on other cell types in these tissues 
(blood vessels, immune cells).
(VI) In some of the long cardiovascular endpoint trials 
there were markedly beneficial effects (40% reductions) 
on renal endpoints (time to macroalbuminuria, doubling 
of serum creatinine, end stage renal disease or renal death) 
(10,16). So, was this an effect of improved metabolic control 
or direct effects on the kidneys? It is generally thought 
that there may be several effects of GLP-1 and the GLP-
1RAs on the kidneys, but receptor expression has only been 
convincingly documented in the afferent arterioles (17). 
In experimental animals, GLP-1 has hemodynamic effects 
consistent with this receptor localization, but in humans 
this has been difficult to demonstrate, both acutely and 
during chronic GLP-1RA therapy. The only action that has 
been well documented in humans is an effect on lithium 
fractional excretion (consistent with inhibited proximal 
sodium reabsorption), although a significantly increased 
sodium excretion has been difficult to demonstrate except 
after fluid and salt challenge (18,19). In a couple of studies, 
there has been a clear inhibitory effect on angiotensin II 
levels, which may play a role (19), and could be consistent 
with the co-expression of renin and GLP-1 R in some cells 
of the juxtaglomerular afferent arterioles. At any rate, the 
renoprotective effects are quite marked, and clearly deserve 
further attendance.
(VII) GLP-1 and the immune system was the subject 
of a recent review in which it was concluded that GLP-1 
may play an important role in inflammation (20). However, 
the field has been confused by reports that IL-6 might be 
essential for mediating GLP-1 secretion and responses 
under inflammatory conditions, but this is not seen in 
humans (21). There are also several reports that GLP-1 
is secreted in response to inflammation, e.g., induced by 
LPS, but this is also controversial (22). However, there is 
agreement that there is a dense expression of the GLP-
1 receptor on intestinal intraepithelial lymphocytes, and 
it is likely that GLP-1 and perhaps also the GLP-1 RAs 
may modulate enteric immune responses via this route and 
link mucosal integrity to innate immunity (23). However, 
if it turns out that the GLP-1 RAs have anti-inflammatory 
actions also in humans, these are likely to contribute to the 
beneficial cardiovascular actions of the agonists (20). 
(VIII) The GLP-1R is also heavily expressed on neurons 
of the enteric nervous system, and this may provide the 
structural substrate for several both motor and vascular 
actions locally in the gut, as well as for ascending sensory 
impulses transmitted to the brain and involved in appetite 
and glucose control (24). Indeed, vagotomy in humans has 
been shown to eliminate the appetite suppressant effects 
of GLP-1 (25), but it must be recognized that the overall 
importance of this pathway, particularly when it comes to 
exogenous GLP-1RAs is uncertain. Indeed, deletion of 
sensory vagal afferents in mice had no influence on the food 
intake inhibiting effects of liraglutide whereas deletion of 
GLP-1 receptor in the brain lead to loss of effects (26).
(IX) The results of cardiovascular outcome trials 
regarding the GLP-1RAs are rolling in. The ELIXA 
trial (27) with lixisenatide was the first, soon to be followed 
by LEADER (10) (liraglutide 1.8 mg), SUSTAIN 6 (16) 
(semaglutide 1.0 mg), EXSCEL (28) (exenatide ow), 
HARMONY (12) (albiglutide) and REWIND (dulaglutide) 
(for REWIND there is so far only a company press 
release). What can we learn regarding the cardiovascular 
effects of the GLP-1 RAs from these trials? First of all, it 
is important to note that these are safety trials design to 
investigate cardiovascular safety of these compounds. The 
first conclusion, therefore, is that they are all safe, i.e., they 
do not increase the risk of a CV event during prolonged 
therapy. All studies had time to MACE, i.e., major adverse 
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cardiovascular events (defined as non-fatal myocardial 
infarction, non-fatal stroke or cardiovascular death) as the 
primary end point. The pleasant surprise is that some of 
the studies actually showed a reduced risk of MACE. In the 
ELIXA trial there was no risk reduction, but this trial was 
of relative short duration, involved a short-acting GLP-
1RA (lixisenatide with few hours’ daily exposure) and the 
patients had extremely high risk of an event (most had acute 
coronary syndrome within the last 90 days of inclusion) (27). 
In the LEADER study (>9,000 patients mostly with 
established CVD treated for at least 3.5 years) there was 
a 13% significant reduction in the risk of MACE, and 
with semaglutide in similar population (>3,000), but for 
2 years only, in SUSTAIN 6, there was a highly significant 
26% reduction. In EXSCEL, there was an 11% reduction 
(P=0.061 in almost 15,000 patients), but a significant 14% 
reduction in all-cause mortality. HARMONY (albiglutide) 
resulted in a highly significant 22% reduction in MACE. For 
REEWIND (dulaglutide), carried out in a population with 
mainly increased CVD risk but without established disease, 
we only have a press release (from Eli Lilly as of November 
11, 2018) stating significant reduction of MACE.
The studies also have looked at  the individual 
components of the MACE, and in the study with the 
strongest risk reduction (SUSTAIN 6) (16), the result 
was driven by significant reductions in stroke and near 
significant reductions in myocardial infarction, and similar 
changes were seen in LEADER (although insignificant). 
Confusing results were observed regarding cardiovascular 
death, where LEADER showed a 22% highly significant 
reduction, while there was absolutely no reduction in 
SUSTAIN 6. One interesting finding in SUSTAIN 6 
was a very significant 35% reduction in revascularization 
procedures. It should also be mentioned that the therapies 
appeared renoprotective with very significant reductions 
in nephropathy risk, e.g., by 36% in SUSTAIN 6, 
where improvements were mainly due to reduced risk 
of albuminuria. In stark contrast to the results obtained 
with the SGLT-2 inhibitors, with empagliflozin being 
an outstanding example (29), there is no effect on heart 
failure by the GLP-1 agonists, whether as a reduced risk 
of MACE among those with heart failure at base line, or 
as a diminished risk of developing heart failure during the 
course of therapy. Indeed, in studies dedicated to study 
the effects of liraglutide in patients with heart failure 
(whether or not in combination with diabetes), there was 
no benefit, rather a tendency to increased risk (30,31). 
Thus, the mechanisms behind the beneficial effects of the 
SGLT-2 inhibitors versus the GLP-1RAs are clearly 
distinct. Since the RA with the strongest CV effect 
is also the one with strongest effects on metabolic 
parameters (body weight and HbA1c), one could suspect 
that metabolic improvement by the GLP-1 RAs play an 
important role. Like in SUSTAIN 6, there was also no 
effect on cardiovascular death in the HARMONY trial, 
whereas the highly significant improvement in MACE 
was driven almost exclusively by reduced risk of AMI. 
Remarkably, in that study (12) there was no effect at 
all on body weight or blood pressure, seemingly ruling 
out these parameters from being responsible for the 
effects. There was however a good effect on A1c. The 
positive results of the REWIND study (and supported 
by the EXSCEL results) suggest that the beneficial 
effects are not only reserved for those with established 
cardiovascular disease, but that reductions in event 
rates can also expected in patients with type 2 diabetes 
and increased risk, but without established disease. 
Unfortunately, there isn’t much help to gain from preclinical 
studies regarding the mechanisms involved. It is almost 
certain that there will be important differences between 
species, and there isn’t a lot of good evidence regarding 
the exact location of the GLP-1 receptor in the human 
heart, although robust expression of the receptor in all 4 
chambers of the human heart was recently reported (32). 
Importantly, there was no receptor expression in cardiac 
fibroblasts or in coronary endothelial or vascular smooth 
muscle cells. The only place where everybody can 
agree that there may be expression is in the sinoatrial 
node (24), which is where the GLP-1RAs are supposed to 
act when they generate increased heart rate, which they 
all do. Clearly, these findings cannot at present be used to 
explain the cardiovascular benefits of the GLP-1 RAs.
However, the great promise is that there is an effect in 
the clinical trials, and currently the best interpretation of 
the data seems to be that the GLP-1 RAs exert an anti-
atherogenic effect, which shows up in a reduced rate of 
myocardial infarctions, sometimes reduced stroke (the good 
effects on blood pressure in the SUSTAIN 6 trial might 
contribute) and perhaps most clearly in the beneficial renal 
effects and the reduced frequency of revascularizations 
procedures (16). So, it may be justified to expect, as you start 
therapy with a GLP-1 RAs, that not only will you obtain a 
strong anti-diabetogenic effect (better than with any other 
agent in the second line of therapies of T2DM), but you 
may also be able to prevent, to some extent, atherosclerotic 
complications from occurring. 
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Thus, there are many good reasons why GLP-1RAs are 
recommended for second line therapy in T2DM.
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